Do you want to read an article? Please log in or register.
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
United European Gastroenterol J.
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A
doi: 10.1177/2050640620929133.
Inflammatory Bowel Disease
Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts
Clin Gastroenterol Hepatol.
Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L
doi: 10.1016/j.cgh.2020.04.071.
Inflammatory Bowel Disease
Could Patients With Inflammatory Bowel Disease Treated with Immunomodulators or Biologics Be at Lower Risk for Severe Forms of Covid-19?
No abstract available
COMMENTED
Inflammatory Bowel Disease
Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gastroenterology.
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD
doi: 10.1053/j.gastro.2020.05.032.
Inflammatory Bowel Disease
Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis
United European Gastroenterol J
Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S
doi: 10.1177/2050640620972602
Inflammatory Bowel Disease
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
Inflamm Bowel Dis.
Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM
doi: 10.1093/ibd/izz001.
Inflammatory Bowel Disease
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis
Clin Gastroenterol Hepatol.
Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ
doi: 10.1016/j.cgh.2019.02.044.
Inflammatory Bowel Disease
Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease
Inflamm Bowel Dis.
Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN
doi: 10.1093/ibd/izz253.
Inflammatory Bowel Disease
Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis
Am J Gastroenterol.
Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, Melmed GY, Spiegel BMR
doi: 10.1038/ajg.2017.470.